Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)

Next Previous
Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 18 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efruxifermin (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms Harmony
  • Sponsors Akero Therapeutics

Most Recent Events

  • 07 Nov 2025 According to a Akero Therapeutics media release, data from this trial will be shared at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025, taking place November 7-11, 2025, in Washington, D.C.
  • 14 Aug 2025 According to a Akero Therapeutics media release, company announced publication of 96-week results from the Phase 2b HARMONY trial in The Lancet.
  • 10 May 2025 According to a Akero Therapeutics media release, the results were published in an oral presentation and a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, in Amsterdam, the Netherlands.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top